Funder
Ispen
Merz
Auspex
Diichi Sankyo Pharma
AbbVie
National Institute of Neurological Disorders and Stroke
Kyowa
Neurocrine, Sunovion Pharmaceuticals
Acadia
Accorda
Cynapsus
Neuroderm
Prexton Therapeutics
Intec
Adamas Pharmaceuticals, Inc.
Allergan, Inc.
Biotie Therapies
CHDI Foundation
Civitas/Acorda Therapeutics
Dystonia Coalition
Dystonia Medical Research Foundation
F. Hoffmann-La Roche Ltd.
Huntington Study Group
Medtronic Neuromodulation
Merz Pharmaceuticals
Michael J Fox Foundation for Parkinson Research
National Institutes of Health
Neurocrine Biosciences
Parkinson's Foundation
Nuvelution
Parkinson Study Group
Pfizer Inc.
Prothena Biosciences Inc.
Psyadon Pharmaceuticals, Inc.
Revance Therapeutics, Inc.
Teva Pharmaceutical Industries Ltd
Subject
Clinical Neurology,Neurology
Reference76 articles.
1. Epidemiology, prevention, and assessment of tardive dyskinesia and advances in treatment;Correll;J. Clin. Psychiatry,2017
2. Neurological symptoms in pharmacotherapy of psychoses;Faurbye;Acta Psychiatr. Scand.,1964
3. Drug-induced dyskinesia, part 2: treatment of tardive dyskinesia;Vijayakumar;Drugs,2016
4. An update on tardive dyskinesia: from phenomenology to treatment;Waln;Tremor Other Hyperkinet Mov (N Y),2013
5. Tardive syndrome;Savitt;J. Neurol. Sci.,2018
Cited by
58 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献